Latest Breaking News On - George kemble - Page 1 : vimarsana.com

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

SAN MATEO, Calif., March 25, 2024 -- Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional...

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of ...

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD

Fresh off its IPO, Sagimet adds two former Cognoa execs to corner office

Sagimet Biosciences (SGMT) Announces Leadership Changes, COO to Assume Position as CFO

Sagimet Biosciences Announces Leadership Changes

Sagimet Biosciences gives going public a second chance under new CEO

Biotech drug developer Sagimet Biosciences is taking another shot at going public, according to a filing with the SEC late Friday.

Published Results from Sagimet's FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640's Ability to Significantly Reduce Excess Liver Fat

Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors

Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors News provided by Share this article Share this article SAN MATEO, Calif., May 3, 2021 /PRNewswire/ -- Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today the appointment of Elizabeth Grammer, Esq., to its board of directors. Ms. Grammer brings to her role as director over 25 years of experience advising privately held and publicly traded life sciences companies at all stages of development. George Kemble, Ph.D., Sagimet's chief executive officer, said, "Elizabeth is a strategic and innovative thinker with a passion for developing, articulating and leading the execution of corporate strategy and will be a great addition to our board. We look forward to leveraging her extensive experience to help Sagimet grow our business."

Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH

Share this article Share this article SAN MATEO, Calif., March 16, 2021 /PRNewswire/ -- Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TVB-2640 for the treatment of patients with NASH. TVB-2640, is a wholly-owned, oral, selective inhibitor of FASN, a key enzyme involved in the production of saturated fatty acids in the liver and other organs, and is the only enzyme in the human body capable of converting metabolized sugars into palmitate.  In patients with NASH, increased FASN-mediated palmitate synthesis in the liver is the source of three key drivers of the disease: excess accumulation of liver fat, inflammation and fibrosis.